Traders Purchase Large Volume of Boston Scientific Call Options (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) saw unusually large options trading activity on Thursday. Traders purchased 44,506 call options on the company. This represents an increase of 46% compared to the typical daily volume of 30,418 call options.

Analyst Upgrades and Downgrades

BSX has been the topic of several analyst reports. Canaccord Genuity Group dropped their price target on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. UBS Group decreased their target price on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Leerink Partners cut their price target on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a report on Thursday, May 28th. Finally, Needham & Company LLC reissued a “buy” rating and set a $77.00 target price on shares of Boston Scientific in a research note on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.36.

Boston Scientific Trading Down 0.1%

NYSE:BSX opened at $44.16 on Friday. The company’s 50 day moving average is $52.87 and its 200-day moving average is $71.13. Boston Scientific has a 12 month low of $43.89 and a 12 month high of $109.50. The firm has a market cap of $65.64 billion, a price-to-earnings ratio of 18.48, a P/E/G ratio of 0.85 and a beta of 0.56. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the previous year, the business posted $0.75 EPS. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts anticipate that Boston Scientific will post 3.36 EPS for the current year.

Boston Scientific announced that its Board of Directors has approved a share buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In related news, Director David C. Habiger bought 2,250 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. The trade was a 19.35% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 9,800 shares of company stock valued at $554,012 over the last quarter. Insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Institutional investors and hedge funds have recently bought and sold shares of the business. Basecamp Wealth Advisors LLC raised its position in Boston Scientific by 45.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 3,740 shares of the medical equipment provider’s stock worth $235,000 after purchasing an additional 1,170 shares in the last quarter. Ballast Advisors LLC bought a new stake in Boston Scientific in the first quarter valued at $62,000. Lombard Odier Asset Management Europe Ltd raised its stake in Boston Scientific by 5.7% during the first quarter. Lombard Odier Asset Management Europe Ltd now owns 151,463 shares of the medical equipment provider’s stock worth $9,504,000 after acquiring an additional 8,184 shares in the last quarter. Rathbones Group PLC lifted its holdings in shares of Boston Scientific by 15.2% during the first quarter. Rathbones Group PLC now owns 3,179,435 shares of the medical equipment provider’s stock valued at $199,510,000 after acquiring an additional 419,778 shares during the period. Finally, First National Bank of Mount Dora Trust Investment Services bought a new position in shares of Boston Scientific during the first quarter valued at $8,455,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.